• Decoy Therapeutics will hold a virtual special stockholder meeting on Sept. 14, 2026.
• Vote scheduled on allowing exercise of Series A, Series B, Series C common warrants from a June 2026 private placement.
• Proposal would permit issuance of up to 2,961,085 common shares on warrant exercise, potentially generating up to about $17.5 million in gross proceeds.
• Stockholders will also vote on cutting authorized common shares to 90,000,000 from 100,000,000.
• Meeting includes a proposal to adjourn, if needed, to seek additional proxy support.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-332762), on August 04, 2026, and is solely responsible for the information contained therein.